The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
agree with that bignose.i had been expecting the usual pullback for two or three days(i know we've been closed for the odd day)but quite a strong performance today i thought.
Interesting to see how Friday pans out. Certainly doesn't appear to be the usual P&D and certainly no sign of Heimdal to help it on its way, which could be a good sign....lol
Actually for the last week it has been edging up, although I feel its being held back. There was even a 1.4mill share trade which didn't spike the sp. It reached 0.11 at some time which is the highest in the recent sessions.
Anyway, long may it continue.
agree with that bignose.i suppose they could have some sort of pre approval. im just sceptical,although no real reason to be (ha ha). just on the trades today about 40% by volume took place at 0.104 hkd or above. not suggesting its particularly significant but interesting. very good site aastocks. .thanks again for putting me onto it.(seems like a lifetime ago!)
The.Italian, I’m sure they wouldn’t commence phase III without knowing it was ok (imagine the consequences with the FDA if it was not). Maybe the FDA have already agreed its ok to commence ?
very good point Escovido.
https://www.centerwatch.com/clinical-trials/overview morning bignose. good to see a more positive tone today.no idea if you can actually start phase 3 before completing phase 2. this article would suggest not.results have to be sent to FDA before starting next phase, but its perhaps not categorical. we shall see. what is clear is there is a more solid feel to the market over the last few sessions.large percentage of trades taking place at over 0.10 .hkd. fingers crossed that its firming up and good to hear about mike wylie.
Massive unemployment in USA at the mo, so that might help?
Seems they are pretty confident in recruiting the numbers by the said date. Could this be change our fortunes ? Certainly a week of increased volume suggests some local investors believe so.
The.Italian
Apparently, JG believes that if patients can be "magically" recruited by August 1st, the P2 study will be completed by the end of Sept and in the meantime they will take a "risk" and crack on with P3 prior to the P2 readouts. (they must be pretty confident of readout results). Also to note. Dr Mike was very positive about multiples in SP last time we had contact several weeks ago, which he has never been so positive about before.
Given that it was also announced that the Group’s strategy remains to continue negotiations with potential commercial strategic partners for the US market while we undertake the clinical work with the aim of securing a partner "just ahead of", could well indicate a licensee is waiting with pen in hand ???
However, as you state, there is a fat chance of that happening if they only managed 30 in 12 months and are expecting another 44 in only 3 !!!
One can only live in hope that they are finally running out of lies....... LOL
pleasure prof z.i think the " best" summary of the USA position is in the first section of the operations update on18/6/20/.however the time scale for completing recruitment by end of august looks decidedly optomistic given the time taken to complete the first tranch of participants. even if it could be completed by then, the suggestion that pivotal phase 111 work could commence in 2020 must clearly be a mistake.we won't have completed phase11 by then. they seem to have taken the2020 date from previous announcements, which is beyond sloppy.i suppose it is just possible that the final date of q3 2023 for approval is just about possible,but only if everything went on time and without problems. personally i wouldn't expect approval before say q3 2024.this is just my take of course and i could be wrong. no advice intended and at least the update doesn't seem to have produced the fall in the s/p that it might have done, so perhaps bad news,low expectations and innacurate announcements are already priced in.gla
Much appreciated, Italian, good to see you are well too!
What is the position on the US? I imagine things are going to be set back considerably on the Fortacin front. I'm a little disappointed that we couldn't have done something more positive during these strange times as we are supposed to be a pharmaceutical or at least have links to them.
morning professorZ.glad to hear you are out of quarantine and have got through this difficult time.not sure im the best person to update you but over the last 3 months we have had final results on 31st march(on website)which were,to put it mildly ,pretty awful. slow decline in s/p on very low volume generally.i think there was a spike 3 or 4 weeks ago but it didnt hold.then we had a trading update on18th june(on website).largely repeated previous information but is essential reading really as it contains quite lot of detail and update on FDA trial recruitment .unfortunately it contains what appears to be a glaring error about FDA timelines.anyway we have then had a spike on quite large volume,much more than for a long time. since then we have gone down and now back up again on modest volume ,but better than we were experiencing generally.so pleasing to see s/p up from its lows of a little while ago but no substantive positive news to support it.next news expected is update on ema application for change from RX to oct,expected i think by end of july.personally i think this is very important but not confident we will get it(although trading update did sound reasonably positive) if you read the t/u that will bring you up to date.happy to be corrected if anything I've said from memory is wrong or I've missed anything vital .
Not a lot!
Good to see the same names on the recent posts, have been concentrating on other things more recently to have had the time to post, but thought I'd check-in and see how the mood was.
Glad to see that there is life in the share still with a 10%+ gain according to my information overnight, perhaps there may be some value left in them after all, but I'm certainly not going to hold out too much hope.
Rather than read through 3 months of posts, can anyone summarise in a paragraph what I've missed please?